News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Protox Therapeutics Inc. Appoints Dr. Samuel Denmeade as Chief Scientific Officer
October 22, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
VANCOUVER, Oct. 22 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX) today announced that it has appointed Dr. Samuel Denmeade to the position of Chief Scientific Officer, effective immediately.
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
Manufacturing
Lilly and Boehringer roll back billions in German investments over health budget cuts
June 4, 2026
·
2 min read
·
Nick Paul Taylor
IPO
Peptide biotech Parabilis targets up to $476M IPO
June 4, 2026
·
2 min read
·
Gabrielle Masson
Artificial intelligence
Alnylam hops on AI train with up to $2B Inceptive partnership
June 4, 2026
·
1 min read
·
Tristan Manalac
Insights
Rethinking hair loss treatment
June 4, 2026
·
1 min read
·
Jennifer C. Smith-Parker
